These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34117987)

  • 1. Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.
    Federici C; Reckers-Droog V; Ciani O; Dams F; Grigore B; Kaló Z; Kovács S; Shatrov K; Brouwer W; Drummond M
    Eur J Health Econ; 2021 Nov; 22(8):1253-1273. PubMed ID: 34117987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.
    Kovács S; Kaló Z; Daubner-Bendes R; Kolasa K; Hren R; Tesar T; Reckers-Droog V; Brouwer W; Federici C; Drummond M; Zemplényi AT
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):195-206. PubMed ID: 35322478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coverage with evidence development for medical devices in Europe: Can practice meet theory?
    Drummond M; Federici C; Reckers-Droog V; Torbica A; Blankart CR; Ciani O; Kaló Z; Kovács S; Brouwer W
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):179-194. PubMed ID: 35220644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
    Daubner-Bendes R; Kovács S; Niewada M; Huic M; Drummond M; Ciani O; Blankart CR; Mandrik O; Torbica A; Yfantopoulos J; Petrova G; Holownia-Voloskova M; Taylor RS; Al M; Piniazhko O; Lorenzovici L; Tarricone R; Zemplényi A; Kaló Z
    Front Public Health; 2020; 8():612410. PubMed ID: 33490024
    [No Abstract]   [Full Text] [Related]  

  • 5. Special funding schemes for innovative medical devices in French hospitals: the pros and cons of two different approaches.
    Martelli N; van den Brink H
    Health Policy; 2014 Jul; 117(1):1-5. PubMed ID: 24794738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage with evidence development: the Ontario experience.
    Levin L; Goeree R; Levine M; Krahn M; Easty T; Brown A; Henry D
    Int J Technol Assess Health Care; 2011 Apr; 27(2):159-68. PubMed ID: 21473814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coverage with Evidence Development: applications and issues.
    Trueman P; Grainger DL; Downs KE
    Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [European Collaboration in Medical Device Assessment: One Step Towards Cross-Border Health Care].
    Mayer J; Ettinger S; Nachtnebel A
    Gesundheitswesen; 2018 Mar; 80(3):210-216. PubMed ID: 28628932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013.
    Brügger U; Horisberger B; Ruckstuhl A; Plessow R; Eichler K; Gratwohl A
    BMJ Open; 2015 Mar; 5(3):e007021. PubMed ID: 25818273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
    Pouwels XGLV; Grutters JPC; Bindels J; Ramaekers BLT; Joore MA
    Value Health; 2019 Jul; 22(7):799-807. PubMed ID: 31277827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey.
    García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R
    Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HTA of medical devices: Challenges and ideas for the future from a European perspective.
    Fuchs S; Olberg B; Panteli D; Perleth M; Busse R
    Health Policy; 2017 Mar; 121(3):215-229. PubMed ID: 27751533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pushing the boundaries of evaluation, diffusion, and use of medical devices in Europe: Insights from the COMED project.
    Torbica A; Tarricone R; Schreyögg J; Drummond M
    Health Econ; 2022 Sep; 31 Suppl 1():1-9. PubMed ID: 36068719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.
    Marsh K; van Til JA; Molsen-David E; Juhnke C; Hawken N; Oehrlein EM; Choi YC; Duenas A; Greiner W; Haas K; Hiligsmann M; Hockley KS; Ivlev I; Liu F; Ostermann J; Poder T; Poon JL; Muehlbacher A
    Value Health; 2020 Jul; 23(7):831-841. PubMed ID: 32762984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing a new taxonomic model for the assessment of medical devices: Is it plausible and applicable? Insights from HTA reports and interviews with HTA institutions in Europe.
    Fuchs S; Olberg B; Perleth M; Busse R; Panteli D
    Health Policy; 2019 Feb; 123(2):173-181. PubMed ID: 29703653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
    Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
    Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues.
    Martelli N; van den Brink H; Borget I
    Value Health; 2016 Jan; 19(1):17-9. PubMed ID: 26797231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.